OLPRUVA Trademark

Trademark Overview

On Friday, February 28, 2020, a trademark application was filed for OLPRUVA with the United States Patent and Trademark Office. The USPTO has given the OLPRUVA trademark a serial number of 88814846. The federal status of this trademark filing is REGISTERED as of Tuesday, August 29, 2023. This trademark is owned by Acer Therapeutics Inc.. The OLPRUVA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for the treatment of inborn errors of metabolism
olpruva

General Information

Serial Number88814846
Word MarkOLPRUVA
Filing DateFriday, February 28, 2020
Status700 - REGISTERED
Status DateTuesday, August 29, 2023
Registration Number7151227
Registration DateTuesday, August 29, 2023
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 23, 2020

Trademark Statements

Goods and ServicesPharmaceuticals for the treatment of inborn errors of metabolism

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, March 6, 2020
Primary Code005
First Use Anywhere DateThursday, July 13, 2023
First Use In Commerce DateThursday, July 13, 2023

Trademark Owner History

Party NameAcer Therapeutics Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressNewton, MA 02458
Party NameAcer Therapeutics Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNewton, MA 02458
Party NameAcer Therapeutics Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNewton, MA 02458

Trademark Events

Event DateEvent Description
Tuesday, August 29, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, August 29, 2023REGISTERED-PRINCIPAL REGISTER
Tuesday, July 25, 2023NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Sunday, July 23, 2023ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, July 18, 2023STATEMENT OF USE PROCESSING COMPLETE
Friday, July 14, 2023USE AMENDMENT FILED
Friday, July 14, 2023TEAS STATEMENT OF USE RECEIVED
Tuesday, February 28, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 27, 2023SOU EXTENSION 5 GRANTED
Wednesday, February 8, 2023SOU EXTENSION 5 FILED
Monday, February 27, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, February 8, 2023SOU TEAS EXTENSION RECEIVED
Friday, July 29, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 27, 2022SOU EXTENSION 4 GRANTED
Wednesday, July 27, 2022SOU EXTENSION 4 FILED
Wednesday, July 27, 2022SOU TEAS EXTENSION RECEIVED
Friday, February 11, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 9, 2022SOU EXTENSION 3 GRANTED
Wednesday, February 9, 2022SOU EXTENSION 3 FILED
Wednesday, February 9, 2022SOU TEAS EXTENSION RECEIVED
Friday, August 13, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 11, 2021SOU EXTENSION 2 GRANTED
Wednesday, August 11, 2021SOU EXTENSION 2 FILED
Wednesday, August 11, 2021SOU TEAS EXTENSION RECEIVED
Friday, February 12, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 10, 2021SOU EXTENSION 1 GRANTED
Wednesday, February 10, 2021SOU EXTENSION 1 FILED
Wednesday, February 10, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, August 18, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 23, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 23, 2020PUBLISHED FOR OPPOSITION
Wednesday, June 3, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, May 20, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 19, 2020ASSIGNED TO EXAMINER
Friday, March 6, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Related Keywords

olpruva metabolism errors inborn treatment pharmaceuticals